Vertex to acquire ViaCyte
Vertex to acquire ViaCyte, with the goal of accelerating its potentially curative VX-880 programmes in Type 1 diabetes. ViaCyte brings tools, technologies and assets with
Vertex to acquire ViaCyte, with the goal of accelerating its potentially curative VX-880 programmes in Type 1 diabetes. ViaCyte brings tools, technologies and assets with